Attached files
file | filename |
---|---|
8-K - FORM 8-K - NovaBay Pharmaceuticals, Inc. | nby20180207_8k.htm |
Exhibit 99.1
NovaBay Pharmaceuticals Completes $6.0 Million Private Placement
EMERYVILLE, Calif. (February 12, 2018) – NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focused on commercializing Avenova®, a prescription product for the domestic eye care market, announces the completion of a private placement of 1.7 million shares of common stock to OP Financial Investment Limited for gross proceeds of $5,984,000. OP Financial Investment Limited is an institutional investor listed on the Main Board of Hong Kong Stock Exchange (Stock code: 01140) focused on cross-border investment opportunities. China Kington Asset Management Co. Ltd. served as placement agent for the financing.
“We believe our investment in NovaBay provides OP Financial with unique insight and fresh experience in drug commercialization, as well as an opportunity to become more familiar with the U.S. pharmaceutical industry,” said OP Financial CEO Zhang Gaobo.
Eric (Bing) Wu, Partner and Senior VP at China Kington Asset Management Co. Ltd., stated, “China Kington is proud to be the financial partner of NovaBay and this transaction aligns with our commitment to connect U.S. public companies with the financial resources in China and Hong Kong. We will continue to play an active role between U.S. biopharmaceutical companies and China’s financial market.”
“We are pleased to complete this financing on favorable terms to NovaBay with an investor that shares our focus on the significant long-term potential of Avenova,” said Mark M. Sieczkarek, NovaBay’s Chairman, President and CEO. “While our previously announced $10.32 million private placement with Ch-gemstone Capital expired due to an issue with foreign investments by Chinese funds, we are pleased to offer this opportunity to OP Financial and are delighted to welcome them as a new shareholder. We thank China Kington for its continued commitment to our success.”
About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®
Forward-Looking Statements
|
Socialize and Stay informed on NovaBay’s progress:
Like us on Facebook
Follow us on Twitter
Connect with NovaBay on LinkedIn
Join us on Google +
Visit NovaBay’s Website
NovaBay Contacts
For NovaBay Avenova purchasing information:
Please Call us toll free: 1-800-890-0329 or email sales@avenova.com.
From the Company
Jack McGovern
Chief Financial Officer
510-899-8800
jmcgovern@novabay.com
Investor Contact
LHA
Jody Cain
310-691-7100
jcain@lhai.com
###